DrugDDI.d10.s10.d0$Cyclosporine$DB00091$Nicardipine$DB00622$Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
DrugDDI.d100.s2.d0$Diazoxide$DB01119$Hydralazine$DB01275$Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
DrugDDI.d100.s5.d0$Propranolol$DB00571$Hydralazine$DB01275$Propranolol increases hydralazines serum concentrations.
DrugDDI.d102.s0.d0$Calcium$DB01373$L-Lysine$DB00123$Concomitant use of calcium supplements and L-lysine may increase calcium absorption
DrugDDI.d105.s6.d1$Pseudoephedrine$DB00852$Kaolin$DB01575$Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
DrugDDI.d107.s0.d0$Loracarbef$DB00447$Probenecid$DB01032$Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
DrugDDI.d109.s4.d0$Colestipol$DB00375$Atorvastatin$DB01076$Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
DrugDDI.d109.s5.d0$Atorvastatin$DB01076$Colestipol$DB00375$However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
DrugDDI.d109.s6.d0$Atorvastatin$DB01076$Cimetidine$DB00501$Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
DrugDDI.d109.s7.d0$Atorvastatin$DB01076$Digoxin$DB00390$Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
DrugDDI.d109.s9.d0$Atorvastatin$DB01076$Erythromycin$DB00199$Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
DrugDDI.d11.s0.d1$Kaolin$DB01575$Chloroquine$DB00608$Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
DrugDDI.d11.s2.d0$Cimetidine$DB00501$Chloroquine$DB00608$Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
DrugDDI.d11.s4.d0$Chloroquine$DB00608$Ampicillin$DB00415$Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
DrugDDI.d110.s0.d0$Probenecid$DB01032$Acyclovir$DB00787$Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
DrugDDI.d117.s1.d0$Flexeril$DB00924$Alcohol$DB00898$FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
DrugDDI.d118.s1.d0$Ergotamine$DB00696$Frova$DB00998$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DrugDDI.d118.s1.d1$Dihydroergotamine$DB00320$Frova$DB00998$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DrugDDI.d122.s4.d0$Cimetidine$DB00501$Alfenta$DB00802$Cimetidine reduces the clearance of ALFENTA.
DrugDDI.d127.s2.d0$Phenytoin$DB00252$Calcitriol$DB00136$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DrugDDI.d127.s2.d1$Phenobarbital$DB01174$Calcitriol$DB00136$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DrugDDI.d127.s3.d0$Calcitriol$DB00136$Rocaltrol$DB00136$Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
DrugDDI.d128.s5.d0$Buprenorphine$DB00921$Subutex$DB00921$In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
DrugDDI.d13.s8.d1$Dapsone$DB00250$Pyrimethamine$DB00205$With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
DrugDDI.d131.s1.d0$Digoxin$DB00390$Adenocard$DB00640$Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
DrugDDI.d131.s4.d1$Adenosine$DB00640$Caffeine$DB00201$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DrugDDI.d131.s4.d2$Adenosine$DB00640$Theophylline$DB00277$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DrugDDI.d131.s6.d0$Adenosine$DB00640$Dipyridamole$DB00975$Adenosine effects are potentiated by dipyridamole.
DrugDDI.d131.s7.d0$Adenosine$DB00640$Dipyridamole$DB00975$Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
DrugDDI.d133.s2.d0$Ketoconazole$DB01026$Bexarotene$DB00307$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DrugDDI.d133.s2.d1$Erythromycin$DB00199$Bexarotene$DB00307$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DrugDDI.d133.s3.d0$Rifampin$DB01045$Bexarotene$DB00307$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DrugDDI.d133.s3.d1$Phenytoin$DB00252$Bexarotene$DB00307$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DrugDDI.d133.s3.d2$Phenobarbital$DB01174$Bexarotene$DB00307$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DrugDDI.d133.s4.d0$Targretin$DB00307$Gemfibrozil$DB01241$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
DrugDDI.d133.s4.d1$Targretin$DB00307$Bexarotene$DB00307$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
DrugDDI.d133.s4.d2$Gemfibrozil$DB01241$Bexarotene$DB00307$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
DrugDDI.d133.s4.d3$Bexarotene$DB00307$Gemfibrozil$DB01241$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
DrugDDI.d133.s6.d0$Gemfibrozil$DB01241$Targretin$DB00307$Concomitant administration of gemfibrozil with Targretin ? capsules is not recommended.
DrugDDI.d134.s1.d0$Ergotamine$DB00696$Naratriptan$DB00952$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DrugDDI.d134.s1.d1$Dihydroergotamine$DB00320$Naratriptan$DB00952$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DrugDDI.d136.s0.d1$Enablex$DB00496$Ketoconazole$DB01026$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DrugDDI.d136.s0.d2$Enablex$DB00496$Itraconazole$DB01167$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DrugDDI.d136.s0.d3$Enablex$DB00496$Ritonavir$DB00503$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DrugDDI.d136.s0.d4$Enablex$DB00496$Nelfinavir$DB00220$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DrugDDI.d136.s0.d5$Enablex$DB00496$Clarithromycin$DB01211$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DrugDDI.d136.s1.d1$Enablex$DB00496$Flecainide$DB01195$Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
DrugDDI.d136.s1.d2$Enablex$DB00496$Thioridazine$DB00679$Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
DrugDDI.d137.s4.d0$Probenecid$DB01032$Cefdinir$DB00535$Probenecid As with other b span class= c233 -lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
DrugDDI.d140.s0.d0$Digoxin$DB00390$Cyclophosphamide$DB00531$Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.
DrugDDI.d140.s0.d1$Digoxin$DB00390$Vincristine$DB00541$Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.
DrugDDI.d140.s0.d2$Digoxin$DB00390$Prednisone$DB00635$Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.
DrugDDI.d146.s4.d0$d-amphetamine$DB01576$Desipramine$DB01151$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DrugDDI.d147.s2.d0$Quinidine$DB00908$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d1$Verapamil$DB00661$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d2$Amiodarone$DB01118$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d3$Propafenone$DB01182$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d4$Indomethacin$DB00328$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d5$Itraconazole$DB01167$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d6$Alprazolam$DB00404$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s2.d7$Spironolactone$DB00421$Digoxin$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DrugDDI.d147.s3.d0$Erythromycin$DB00199$Digoxin$DB00390$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DrugDDI.d147.s3.d1$Clarithromycin$DB01211$Digoxin$DB00390$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DrugDDI.d147.s3.d3$Tetracycline$DB00759$Digoxin$DB00390$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DrugDDI.d147.s5.d0$Propantheline$DB00782$Digoxin$DB00390$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
DrugDDI.d147.s5.d1$Diphenoxylate$DB01081$Digoxin$DB00390$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
DrugDDI.d147.s6.d2$Sulfasalazine$DB00795$Digoxin$DB00390$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DrugDDI.d147.s6.d3$Neomycin$DB00994$Digoxin$DB00390$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DrugDDI.d147.s6.d4$Cholestyramine$DB01432$Digoxin$DB00390$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DrugDDI.d147.s6.d5$Metoclopramide$DB01233$Digoxin$DB00390$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DrugDDI.d147.s7.d0$Rifampin$DB01045$Digoxin$DB00390$Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
DrugDDI.d155.s0.d0$Cholestyramine$DB01432$Phenylbutazone$DB00812$Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DrugDDI.d155.s0.d1$Cholestyramine$DB01432$Warfarin$DB00682$Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DrugDDI.d155.s0.d3$Cholestyramine$DB01432$Propranolol$DB00571$Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DrugDDI.d155.s0.d4$Cholestyramine$DB01432$Tetracycline$DB00759$Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DrugDDI.d155.s0.d5$Cholestyramine$DB01432$Phenobarbital$DB01174$Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DrugDDI.d155.s0.d8$Cholestyramine$DB01432$Estrogens$DB00286$Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DrugDDI.d156.s2.d0$Doxylamine$DB00366$Epinephrine$DB00668$Doxylamine may enhance the effects of epinephrine.
DrugDDI.d157.s0.d0$Chlorprothixene$DB01239$Lithium$DB01356$Chlorprothixene may increase the plasma-level of concomitantly given lithium.
DrugDDI.d157.s3.d0$Chlorprothixene$DB01239$Tramadol$DB00193$Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
DrugDDI.d159.s10.d0$Probenecid$DB01032$Naproxen$DB00788$Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
DrugDDI.d159.s12.d0$Naproxen$DB00788$Methotrexate$DB00563$Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
DrugDDI.d159.s6.d0$Naproxen$DB00788$Aspirin$DB00945$Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
DrugDDI.d159.s8.d0$Lithium$DB01356$Lithium$DB01356$Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.
DrugDDI.d159.s9.d0$Naproxen$DB00788$Propranolol$DB00571$Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
DrugDDI.d160.s0.d0$Calcium$DB01373$Emcyt$DB01196$Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
DrugDDI.d162.s10.d0$Ketoconazole$DB01026$Cyclosporine$DB00091$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
DrugDDI.d162.s10.d1$Ketoconazole$DB01026$Methylprednisolone$DB00959$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
DrugDDI.d162.s18.d0$Digoxin$DB00390$Ketoconazole$DB01026$It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
DrugDDI.d162.s22.d0$Ketoconazole$DB01026$Phenytoin$DB00252$Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
DrugDDI.d162.s24.d0$Rifampin$DB01045$Ketoconazole$DB01026$Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
DrugDDI.d162.s25.d0$Isoniazid$DB00951$Ketoconazole$DB01026$INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
DrugDDI.d162.s3.d0$Ketoconazole$DB01026$Terfenadine$DB00342$The following drug interactions have been identified involving NIZORAL span class= c97 ? Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
DrugDDI.d162.s31.d0$Disulfiram$DB00822$Alcohol$DB00898$Rare cases of a disulfiram-like reaction to alcohol have been reported.
DrugDDI.d162.s5.d0$Ketoconazole$DB01026$Astemizole$DB00637$Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
DrugDDI.d162.s6.d0$Astemizole$DB00637$Ketoconazole$DB01026$Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
DrugDDI.d162.s7.d0$Ketoconazole$DB01026$Cisapride$DB00604$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
DrugDDI.d162.s8.d0$Ketoconazole$DB01026$Cisapride$DB00604$Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DrugDDI.d162.s9.d0$Ketoconazole$DB01026$Cisapride$DB00604$Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
DrugDDI.d163.s7.d0$Dantrolene$DB01219$Vecuronium$DB01339$Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
DrugDDI.d164.s0.d0$Etanercept$DB00005$Anakinra$DB00026$Concurrent administration of etanercept (another TNF?-blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
DrugDDI.d164.s1.d0$Remicade$DB00065$Anakinra$DB00026$Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
DrugDDI.d165.s8.d0$Cholestyramine$DB01432$T4$DB00451$Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
DrugDDI.d166.s4.d1$Ethacrynic acid$DB00903$Warfarin$DB00682$A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
DrugDDI.d169.s10.d0$Isoniazid$DB00951$Phenytoin$DB00252$Phenytoin: Isoniazid may increase serum levels of phenytoin.
DrugDDI.d169.s12.d0$Isoniazid$DB00951$Theophylline$DB00277$Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
DrugDDI.d169.s14.d0$Valproate$DB00313$Isoniazid$DB00951$Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
DrugDDI.d169.s15.d0$Isoniazid$DB00951$Valproate$DB00313$Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
DrugDDI.d169.s3.d0$Isoniazid$DB00951$Acetaminophen$DB00316$It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
DrugDDI.d169.s5.d0$Isoniazid$DB00951$Acetaminophen$DB00316$Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
DrugDDI.d169.s7.d0$Isoniazid$DB00951$Carbamazepine$DB00564$Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
DrugDDI.d169.s8.d0$Ketoconazole$DB01026$Isoniazid$DB00951$Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
DrugDDI.d169.s9.d0$Ketoconazole$DB01026$Isoniazid$DB00951$When Ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent Isoniazid and Rifampin therapy.
DrugDDI.d172.s0.d0$Aspirin$DB00945$Fenoprofen$DB00573$The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
DrugDDI.d172.s2.d0$Aspirin$DB00945$Nalfon$DB00573$Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
DrugDDI.d172.s3.d0$Phenobarbital$DB01174$Fenoprofen$DB00573$Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
DrugDDI.d172.s4.d0$Phenobarbital$DB01174$Nalfon$DB00573$When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
DrugDDI.d173.s15.d0$Potassium$DB01345$Enalapril$DB00584$Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril.
DrugDDI.d173.s17.d0$Enalapril$DB00584$Lithium$DB01356$A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril/enalapril IV and lithium and were reversible upon discontinuation of both drugs.
DrugDDI.d173.s17.d1$Enalapril$DB00584$Lithium$DB01356$A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril/enalapril IV and lithium and were reversible upon discontinuation of both drugs.
DrugDDI.d173.s18.d0$Enalapril$DB00584$Lithium$DB01356$It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
DrugDDI.d175.s3.d1$Caffeine$DB00201$Cimetidine$DB00501$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DrugDDI.d175.s3.d2$Caffeine$DB00201$Ketoconazole$DB01026$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DrugDDI.d175.s3.d4$Caffeine$DB00201$Phenobarbital$DB01174$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DrugDDI.d175.s3.d5$Caffeine$DB00201$Phenytoin$DB00252$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DrugDDI.d175.s4.d0$Caffeine$DB00201$Ketoprofen$DB01009$Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
DrugDDI.d179.s2.d0$Revia$DB00704$Disulfiram$DB00822$The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
DrugDDI.d179.s3.d0$Revia$DB00704$Thioridazine$DB00679$Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
DrugDDI.d180.s11.d0$Metoclopramide$DB01233$LEVODOPA$DB01235$Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
DrugDDI.d180.s6.d3$Risperidone$DB00734$LEVODOPA$DB01235$Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DrugDDI.d180.s6.d4$Isoniazid$DB00951$LEVODOPA$DB01235$Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DrugDDI.d180.s7.d0$LEVODOPA$DB01235$Phenytoin$DB00252$In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
DrugDDI.d183.s16.d0$Chlorpromazine$DB00477$Dopamine$DB00988$Chlorpromazine - Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
DrugDDI.d183.s17.d0$Ethosuximide$DB00593$Ethosuximide$DB00593$Ethosuximide - Amphetamines may delay intestinal absorption of ethosuximide.
DrugDDI.d183.s20.d0$Meperidine$DB00454$Meperidine$DB00454$Meperidine - Amphetamines pone the analgesic effect of meperidine.
DrugDDI.d183.s22.d0$Norepinephrine$DB00368$Norepinephrine$DB00368$Norepinephrine - Amphetamines enhance the adrenergic effect of norepinephrine.
DrugDDI.d183.s23.d0$Phenobarbital$DB01174$Phenobarbital$DB01174$Phenobarbital - Amphetamines may delay intestinal absorption of phenobarbital;
DrugDDI.d183.s9.d0$d-amphetamine$DB01576$Desipramine$DB01151$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DrugDDI.d186.s0.d0$Diclofenac$DB00586$Aspirin$DB00945$Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
DrugDDI.d186.s18.d0$Diclofenac$DB00586$SALICYLIC ACID$DB00936$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DrugDDI.d186.s18.d1$Diclofenac$DB00586$Tolbutamide$DB01124$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DrugDDI.d186.s18.d2$Diclofenac$DB00586$Prednisolone$DB00860$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DrugDDI.d186.s18.d3$Diclofenac$DB00586$Warfarin$DB00682$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DrugDDI.d186.s4.d0$Diclofenac$DB00586$Digoxin$DB00390$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine?s nephrotoxicity.
DrugDDI.d186.s4.d1$Diclofenac$DB00586$Methotrexate$DB00563$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine?s nephrotoxicity.
DrugDDI.d186.s5.d0$Diclofenac$DB00586$Digoxin$DB00390$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DrugDDI.d186.s5.d1$Diclofenac$DB00586$Methotrexate$DB00563$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DrugDDI.d186.s5.d2$Diclofenac$DB00586$Cyclosporine$DB00091$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DrugDDI.d186.s9.d0$Diclofenac$DB00586$Lithium$DB01356$In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
DrugDDI.d188.s15.d1$Prinivil$DB00722$Triamterene$DB00384$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DrugDDI.d188.s17.d0$Potassium$DB01345$Prinivil$DB00722$Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL.
DrugDDI.d188.s20.d0$Prinivil$DB00722$Lithium$DB01356$It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
DrugDDI.d19.s1.d0$Norfloxacin$DB01059$Theophylline$DB00277$There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
DrugDDI.d19.s12.d0$Videx$DB00900$Norfloxacin$DB01059$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DrugDDI.d19.s3.d0$Cyclosporine$DB00091$Norfloxacin$DB01059$Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
DrugDDI.d19.s4.d0$Cyclosporine$DB00091$Cyclosporine$DB00091$Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
DrugDDI.d19.s5.d2$Norfloxacin$DB01059$Warfarin$DB00682$Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DrugDDI.d19.s9.d0$Probenecid$DB01032$Norfloxacin$DB01059$Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
DrugDDI.d191.s0.d1$Phospholine Iodide$DB01057$Succinylcholine$DB00202$Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
DrugDDI.d192.s10.d0$Brevibloc$DB00187$Digoxin$DB00390$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DrugDDI.d192.s10.d1$Brevibloc$DB00187$Succinylcholine$DB00202$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DrugDDI.d192.s10.d2$Brevibloc$DB00187$Warfarin$DB00682$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DrugDDI.d192.s13.d0$Brevibloc$DB00187$Verapamil$DB00661$Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
DrugDDI.d192.s15.d0$Brevibloc$DB00187$Dopamine$DB00988$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DrugDDI.d192.s15.d1$Brevibloc$DB00187$Epinephrine$DB00668$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DrugDDI.d192.s15.d2$Brevibloc$DB00187$Norepinephrine$DB00368$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DrugDDI.d192.s4.d0$Digoxin$DB00390$Brevibloc$DB00187$When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
DrugDDI.d192.s6.d0$Brevibloc$DB00187$Morphine$DB00295$When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
DrugDDI.d192.s9.d0$Succinylcholine$DB00202$Brevibloc$DB00187$The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
DrugDDI.d195.s2.d0$Betaseron$DB00068$Antipyrine$DB01435$Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
DrugDDI.d197.s1.d0$Fluothane$DB01159$Tubocurarine$DB01199$FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
DrugDDI.d197.s2.d0$Adrenaline$DB00668$Fluothane$DB01159$Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
DrugDDI.d198.s0.d0$Cyclopentolate$DB00979$Carbachol$DB00411$Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DrugDDI.d198.s0.d1$Cyclopentolate$DB00979$Pilocarpine$DB01085$Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DrugDDI.d202.s3.d0$Triamterene$DB00384$Hydrochlorothiazide$DB00999$Coadministration of triamterene and hydrochlorothiazide capsules resulted in a higher plasma amantadine concentration in a 61 year old man receiving amantadine (amantadine hydrochloride) 100 mg TID for Parkinsons disease.1 It is not known which of the components of triamterene and hydrochlorothiazide capsules contributed to the observation or if related drugs produce a similar response.
DrugDDI.d203.s0.d0$Ranitidine$DB00863$Alendronate$DB00630$Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
DrugDDI.d203.s3.d0$Calcium$DB01373$Alendronate$DB00630$Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
DrugDDI.d204.s3.d0$Propranolol$DB00571$Ergotamine$DB00696$Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45? (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
DrugDDI.d206.s1.d0$Peganone$DB00754$Phenurone$DB01121$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
DrugDDI.d206.s1.d1$Peganone$DB00754$Phenacemide$DB01121$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
DrugDDI.d209.s0.d0$Elspar$DB00023$Methotrexate$DB00563$Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
DrugDDI.d215.s0.d0$Thimerosal$DB02731$Latanoprost$DB00654$In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.
DrugDDI.d217.s10.d0$Rifampicin$DB01045$Isradipine$DB00270$If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
DrugDDI.d217.s7.d0$Cimetidine$DB00501$Isradipine$DB00270$Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
DrugDDI.d217.s8.d0$Isradipine$DB00270$Cimetidine$DB00501$If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
DrugDDI.d217.s9.d0$Rifampicin$DB01045$Isradipine$DB00270$Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
DrugDDI.d219.s3.d1$Atromid-S$DB00636$Tolbutamide$DB01124$Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
DrugDDI.d219.s5.d0$Tolbutamide$DB01124$Atromid-S$DB00636$The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
DrugDDI.d22.s1.d0$Amoxapine$DB00543$Alcohol$DB00898$Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants.
DrugDDI.d221.s8.d0$Disulfiram$DB00822$Alcohol$DB00898$In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.
DrugDDI.d225.s2.d0$Irbesartan$DB01029$Aliskiren$DB01258$Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
DrugDDI.d225.s3.d0$Atorvastatin$DB01076$Aliskiren$DB01258$Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
DrugDDI.d225.s4.d0$Ketoconazole$DB01026$Aliskiren$DB01258$Ketoconazole Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
DrugDDI.d225.s9.d0$Aliskiren$DB01258$Furosemide$DB00695$Furosemide When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
DrugDDI.d227.s4.d0$Ciclesonide$DB01410$Ketoconazole$DB01026$In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
DrugDDI.d227.s5.d0$Ketoconazole$DB01026$Ciclesonide$DB01410$Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
DrugDDI.d23.s10.d1$Cyclosporine$DB00091$Pentamidine$DB00738$Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
DrugDDI.d230.s2.d1$Epinephrine$DB00668$Isoproterenol$DB01064$Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
DrugDDI.d230.s5.d2$Epinephrine$DB00668$Halothane$DB01159$Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
DrugDDI.d230.s9.d0$Epinephrine$DB00668$Guanethidine$DB01170$Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
DrugDDI.d231.s12.d0$Furosemide$DB00695$Sucralfate$DB00364$The intake of furosemide and sucralfate should be separated by at least two hours.
DrugDDI.d231.s13.d0$Furosemide$DB00695$Acetylsalicylic acid$DB00945$Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
DrugDDI.d231.s15.d0$Indomethacin$DB00328$Furosemide$DB00695$Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
DrugDDI.d231.s16.d0$Indomethacin$DB00328$Aldosterone$DB04630$Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.
DrugDDI.d231.s17.d0$Indomethacin$DB00328$Furosemide$DB00695$Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
DrugDDI.d231.s2.d0$Furosemide$DB00695$Ethacrynic acid$DB00903$Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
DrugDDI.d231.s4.d0$Furosemide$DB00695$Tubocurarine$DB01199$Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
DrugDDI.d231.s8.d0$Furosemide$DB00695$Norepinephrine$DB00368$Furosemide may decrease arterial responsiveness to norepinephrine.
DrugDDI.d233.s0.d0$Fludara$DB01073$Pentostatin$DB00552$The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
DrugDDI.d236.s3.d1$Capecitabine$DB01101$Phenprocoumon$DB00946$Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
DrugDDI.d236.s5.d0$Fluorouracil$DB00544$Leucovorin$DB00650$Leucovorin The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
DrugDDI.d236.s6.d0$Leucovorin$DB00650$Fluorouracil$DB00544$Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
DrugDDI.d239.s0.d1$Levsin$DB00424$Haloperidol$DB00502$Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DrugDDI.d240.s0.d1$Ponstel$DB00784$Aspirin$DB00945$Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
DrugDDI.d240.s8.d0$Ponstel$DB00784$Furosemide$DB00695$During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
DrugDDI.d245.s1.d0$Lexapro$DB01175$Alcohol$DB00898$Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
DrugDDI.d245.s12.d0$Lithium$DB01356$Escitalopram$DB01175$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
DrugDDI.d245.s12.d1$Lexapro$DB01175$Lithium$DB01356$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
DrugDDI.d245.s17.d0$Sumatriptan$DB00669$Fluoxetine$DB00472$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DrugDDI.d245.s17.d1$Sumatriptan$DB00669$Fluvoxamine$DB00176$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DrugDDI.d245.s17.d2$Sumatriptan$DB00669$Paroxetine$DB00715$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DrugDDI.d245.s17.d3$Sumatriptan$DB00669$Sertraline$DB01104$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DrugDDI.d245.s17.d4$Sumatriptan$DB00669$Citalopram$DB00215$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DrugDDI.d245.s17.d5$Sumatriptan$DB00669$Escitalopram$DB01175$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DrugDDI.d245.s23.d0$Carbamazepine$DB00564$Escitalopram$DB01175$Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
DrugDDI.d245.s25.d0$Citalopram$DB00215$Ketoconazole$DB01026$Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
DrugDDI.d245.s39.d0$Escitalopram$DB01175$Citalopram$DB00215$Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
DrugDDI.d245.s7.d0$Citalopram$DB00215$Cimetidine$DB00501$Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
DrugDDI.d249.s7.d0$Tamoxifen$DB00675$Anastrozole$DB01217$Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY ? Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
DrugDDI.d249.s8.d0$Anastrozole$DB01217$Tamoxifen$DB00675$Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
DrugDDI.d25.s0.d0$Methotrexate$DB00563$Acetaminophen$DB00316$Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
DrugDDI.d25.s2.d0$Gentamicin$DB00798$Gentamicin$DB00798$Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
DrugDDI.d253.s0.d0$Loxapine$DB00408$Lorazepam$DB00186$There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
DrugDDI.d257.s0.d0$Trecator$DB00609$Isoniazid$DB00951$Trecator has been found to temporarily raise serum concentrations of isoniazid.
DrugDDI.d257.s2.d0$Ethionamide$DB00609$Cycloserine$DB00260$In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
DrugDDI.d258.s14.d0$Bupropion$DB01156$Desipramine$DB01151$In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
DrugDDI.d258.s17.d1$Bupropion$DB01156$Nortriptyline$DB00540$Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DrugDDI.d258.s17.d2$Bupropion$DB01156$Desipramine$DB01151$Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DrugDDI.d258.s17.d3$Bupropion$DB01156$Fluoxetine$DB00472$Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DrugDDI.d258.s17.d5$Bupropion$DB01156$Risperidone$DB00734$Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DrugDDI.d258.s20.d0$Bupropion$DB01156$LEVODOPA$DB01235$Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
DrugDDI.d258.s20.d1$Bupropion$DB01156$Amantadine$DB00915$Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
DrugDDI.d258.s22.d2$Wellbutrin$DB01156$Theophylline$DB00277$Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
DrugDDI.d258.s26.d0$Alcohol$DB00898$Wellbutrin$DB01156$The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
DrugDDI.d258.s3.d1$Wellbutrin$DB01156$Orphenadrine$DB01173$Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
DrugDDI.d258.s3.d2$Wellbutrin$DB01156$Cyclophosphamide$DB00531$Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
DrugDDI.d258.s3.d3$Orphenadrine$DB01173$Cyclophosphamide$DB00531$Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
DrugDDI.d258.s5.d0$Cimetidine$DB00501$Bupropion$DB01156$The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.
DrugDDI.d258.s8.d1$Bupropion$DB01156$Carbamazepine$DB00564$While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DrugDDI.d258.s8.d2$Bupropion$DB01156$Phenobarbital$DB01174$While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DrugDDI.d258.s8.d3$Bupropion$DB01156$Phenytoin$DB00252$While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DrugDDI.d26.s2.d0$Dipyridamole$DB00975$Adenosine$DB00640$Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
DrugDDI.d260.s3.d0$Tetracycline$DB00759$Bismuth Subsalicylate$DB01294$Absorption of tetracycline is impaired by bismuth subsalicylate.
DrugDDI.d260.s4.d1$Carbamazepine$DB00564$Doxycycline$DB00254$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
DrugDDI.d260.s4.d2$Phenytoin$DB00252$Doxycycline$DB00254$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
DrugDDI.d260.s5.d0$Tetracycline$DB00759$Penthrane$DB01028$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
DrugDDI.d260.s5.d1$Tetracycline$DB00759$Methoxyflurane$DB01028$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
DrugDDI.d261.s0.d0$Monurol$DB00828$Fosfomycin$DB00828$Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
DrugDDI.d262.s3.d0$Furosemide$DB00695$Flolan$DB01240$In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
DrugDDI.d262.s3.d1$Digoxin$DB00390$Flolan$DB01240$In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
DrugDDI.d262.s5.d0$Digoxin$DB00390$Flolan$DB01240$However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
DrugDDI.d264.s1.d0$Vitamin B12$DB00115$Folic Acid$DB00158$Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
DrugDDI.d266.s0.d1$Probenecid$DB01032$Acetaminophen$DB00316$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d10$Probenecid$DB01032$Famotidine$DB00927$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d11$Probenecid$DB01032$Furosemide$DB00695$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d13$Probenecid$DB01032$Theophylline$DB00277$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d14$Probenecid$DB01032$Zidovudine$DB00495$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d2$Probenecid$DB01032$Acyclovir$DB00787$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d4$Probenecid$DB01032$Aminosalicylic Acid$DB00233$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d7$Probenecid$DB01032$Bumetanide$DB00887$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d8$Probenecid$DB01032$Clofibrate$DB00636$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s0.d9$Probenecid$DB01032$Methotrexate$DB00563$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DrugDDI.d266.s2.d0$Zidovudine$DB00495$Probenecid$DB01032$Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
DrugDDI.d266.s3.d0$Vistide$DB00369$Tobramycin$DB00684$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d266.s3.d1$Vistide$DB00369$Gentamicin$DB00798$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d266.s3.d2$Vistide$DB00369$Amikacin$DB00479$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d266.s3.d3$Vistide$DB00369$Amphotericin B$DB00681$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d266.s3.d4$Vistide$DB00369$Foscarnet$DB00529$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d266.s3.d5$Vistide$DB00369$Pentamidin$DB00738$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d266.s3.d6$Vistide$DB00369$Vancomycin$DB00512$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DrugDDI.d267.s0.d0$Antizol$DB01213$Ethanol$DB00898$Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
DrugDDI.d267.s1.d0$Ethanol$DB00898$Antizol$DB01213$Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
DrugDDI.d267.s2.d1$Antizol$DB01213$Carbamazepine$DB00564$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DrugDDI.d267.s2.d2$Antizol$DB01213$Ketoconazole$DB01026$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DrugDDI.d27.s2.d0$Naltrexone$DB00704$Acamprosate$DB00659$Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
DrugDDI.d277.s0.d0$Erythromycin$DB00199$Theophylline$DB00277$Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
DrugDDI.d277.s1.d0$Theophylline$DB00277$Erythromycin$DB00199$In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
DrugDDI.d277.s10.d1$Erythromycin$DB00199$Astemizole$DB00637$Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
DrugDDI.d277.s12.d0$Terfenadine$DB00342$Erythromycin$DB00199$In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
DrugDDI.d277.s13.d0$Erythromycin$DB00199$Cisapride$DB00604$There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
DrugDDI.d277.s15.d0$Lovastatin$DB00227$Erythromycin$DB00199$Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
DrugDDI.d277.s2.d0$Erythromycin$DB00199$Digoxin$DB00390$Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DrugDDI.d277.s5.d0$Erythromycin$DB00199$Ergotamine$DB00696$Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DrugDDI.d277.s5.d1$Erythromycin$DB00199$Dihydroergotamine$DB00320$Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DrugDDI.d277.s6.d0$Erythromycin$DB00199$Triazolam$DB00897$Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DrugDDI.d277.s6.d1$Erythromycin$DB00199$Midazolam$DB00683$Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DrugDDI.d277.s8.d0$Erythromycin$DB00199$Carbamazepine$DB00564$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d1$Erythromycin$DB00199$Cyclosporine$DB00091$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d10$Erythromycin$DB00199$Valproate$DB00313$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d11$Erythromycin$DB00199$Terfenadine$DB00342$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d12$Erythromycin$DB00199$Astemizole$DB00637$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d2$Erythromycin$DB00199$Tacrolimus$DB00864$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d3$Erythromycin$DB00199$Hexobarbital$DB01355$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d4$Erythromycin$DB00199$Phenytoin$DB00252$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d5$Erythromycin$DB00199$Alfentanil$DB00802$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d6$Erythromycin$DB00199$Cisapride$DB00604$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d7$Erythromycin$DB00199$Disopyramide$DB00280$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d8$Erythromycin$DB00199$Lovastatin$DB00227$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d277.s8.d9$Erythromycin$DB00199$Bromocriptine$DB01200$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DrugDDI.d278.s11.d0$Danazol$DB01406$Lovastatin$DB00227$Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
DrugDDI.d279.s13.d0$Captopril$DB01197$Aldosterone$DB04630$Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.
DrugDDI.d279.s16.d0$Indomethacin$DB00328$Captopril$DB01197$Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
DrugDDI.d279.s6.d0$Nitroglycerin$DB00727$Captopril$DB01197$therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
DrugDDI.d280.s3.d0$Sucralfate$DB00364$Lomefloxacin$DB00978$Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx? (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DrugDDI.d280.s4.d0$Sucralfate$DB00364$Lomefloxacin$DB00978$Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
DrugDDI.d280.s5.d0$Magnesium$DB01378$Lomefloxacin$DB00978$Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
DrugDDI.d287.s0.d0$Ergomar$DB00696$Triacetyloleandomycin$DB01361$The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
DrugDDI.d29.s19.d0$Triazolam$DB00897$Triazolam$DB00897$Triazolam Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
DrugDDI.d29.s20.d0$Erythromycin$DB00199$Digoxin$DB00390$Digoxin Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DrugDDI.d29.s23.d0$Erythromycin$DB00199$Ergotamine$DB00696$Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DrugDDI.d29.s23.d1$Erythromycin$DB00199$Dihydroergotamine$DB00320$Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DrugDDI.d29.s24.d1$Erythromycin$DB00199$Cyclosporine$DB00091$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d10$Erythromycin$DB00199$Lovastatin$DB00227$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d2$Erythromycin$DB00199$Hexobarbital$DB01355$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d3$Erythromycin$DB00199$Carbamazepine$DB00564$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d4$Erythromycin$DB00199$Alfentanil$DB00802$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d5$Erythromycin$DB00199$Disopyramide$DB00280$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d6$Erythromycin$DB00199$Phenytoin$DB00252$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d7$Erythromycin$DB00199$Bromocriptine$DB01200$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d8$Erythromycin$DB00199$Valproate$DB00313$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s24.d9$Erythromycin$DB00199$Astemizole$DB00637$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DrugDDI.d29.s9.d0$Erythromycin$DB00199$Terfenadine$DB00342$Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
DrugDDI.d292.s0.d1$Nabilone$DB00486$Alcohol$DB00898$Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DrugDDI.d292.s1.d0$Nabilone$DB00486$Diazepam$DB00829$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DrugDDI.d292.s1.d1$Nabilone$DB00486$Alcohol$DB00898$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DrugDDI.d293.s0.d1$Tagamet$DB00501$Phenytoin$DB00252$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d2$Tagamet$DB00501$Propranolol$DB00571$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d3$Tagamet$DB00501$Nifedipine$DB01115$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d4$Tagamet$DB00501$Chlordiazepoxide$DB00475$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d5$Tagamet$DB00501$Diazepam$DB00829$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d7$Tagamet$DB00501$Lidocaine$DB00281$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d8$Tagamet$DB00501$Theophylline$DB00277$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d293.s0.d9$Tagamet$DB00501$Metronidazole$DB00916$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DrugDDI.d294.s0.d0$Dimenhydrinate$DB00985$Apomorphine$DB00714$Dimenhydrinate may decrease emetic response to apomorphine.
DrugDDI.d295.s0.d0$Warfarin$DB00682$Griseofulvin$DB00400$Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
DrugDDI.d299.s0.d1$Etonogestrel$DB00294$Acetaminophen$DB00316$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d10$Etonogestrel$DB00294$Trileptal$DB00776$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d11$Etonogestrel$DB00294$Topamax$DB00273$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d12$Etonogestrel$DB00294$Felbatol$DB00949$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d14$Etonogestrel$DB00294$Gris-PEG$DB00400$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d15$Etonogestrel$DB00294$Nizoral$DB01026$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d16$Etonogestrel$DB00294$Sporanox$DB01167$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d17$Etonogestrel$DB00294$Atorvastatin$DB01076$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d18$Etonogestrel$DB00294$Lipitor$DB01076$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d19$Etonogestrel$DB00294$Clofibrate$DB00636$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d2$Etonogestrel$DB00294$Tylenol$DB00316$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d20$Etonogestrel$DB00294$Atromid-S$DB00636$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d21$Etonogestrel$DB00294$Cyclosporine$DB00091$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d22$Etonogestrel$DB00294$Neoral $DB00091$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d23$Etonogestrel$DB00294$Sandimmune $DB00091$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d26$Etonogestrel$DB00294$Agenerase$DB00701$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d27$Etonogestrel$DB00294$Crixivan$DB00224$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d28$Etonogestrel$DB00294$Fortovase$DB01232$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d29$Etonogestrel$DB00294$Invirase$DB01232$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d31$Etonogestrel$DB00294$Norvir$DB00503$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d32$Etonogestrel$DB00294$Viracept$DB00220$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d33$Etonogestrel$DB00294$Morphine$DB00295$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d35$Etonogestrel$DB00294$Kadian$DB00295$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d36$Etonogestrel$DB00294$MS Contin$DB00295$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d37$Etonogestrel$DB00294$Phenylbutazone$DB00812$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d38$Etonogestrel$DB00294$Prednisolone$DB00860$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d39$Etonogestrel$DB00294$Prelone$DB00860$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d4$Etonogestrel$DB00294$Ampicillin$DB00415$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d40$Etonogestrel$DB00294$Rifadin$DB01045$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d41$Etonogestrel$DB00294$Rifampin$DB01045$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d43$Etonogestrel$DB00294$Temazepam$DB00231$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d44$Etonogestrel$DB00294$Theophylline$DB00277$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d45$Etonogestrel$DB00294$Theo-Dur$DB00277$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d46$Etonogestrel$DB00294$Vitamin C$DB00126$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d5$Etonogestrel$DB00294$Tetracycline$DB00759$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d7$Etonogestrel$DB00294$Dilantin$DB00252$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d8$Etonogestrel$DB00294$Phenobarbital$DB01174$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d299.s0.d9$Etonogestrel$DB00294$TEGretol$DB00564$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DrugDDI.d3.s13.d0$Glipizide$DB01067$Fluconazole$DB00196$The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
DrugDDI.d307.s11.d0$Dopamine$DB00988$Propranolol$DB00571$It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
DrugDDI.d307.s4.d1$Dopamine$DB00988$Propranolol$DB00571$Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DrugDDI.d307.s4.d2$Dopamine$DB00988$Metoprolol$DB00264$Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DrugDDI.d307.s7.d1$Haloperidol$DB00502$Dopamine$DB00988$Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
DrugDDI.d309.s0.d0$Cephalexin$DB00567$Metformin$DB00331$Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
DrugDDI.d309.s2.d0$Cephalexin$DB00567$Metformin$DB00331$Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
DrugDDI.d309.s3.d0$Cephalexin$DB00567$Metformin$DB00331$Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
DrugDDI.d309.s4.d0$Cephalexin$DB00567$Probenecid$DB01032$Probenecid As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
DrugDDI.d316.s0.d5$Chlorpromazine$DB00477$Trihexyphenidyl$DB00376$The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DrugDDI.d316.s0.d6$Chlorpromazine$DB00477$Amitriptyline$DB00321$The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DrugDDI.d316.s0.d9$Trihexyphenidyl$DB00376$Amitriptyline$DB00321$The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DrugDDI.d320.s3.d0$Diethylpropion$DB00937$Guanethidine$DB01170$conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DrugDDI.d320.s3.d1$Diethylpropion$DB00937$Methyldopa$DB00968$conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DrugDDI.d321.s1.d0$Auranofin$DB00995$Penicillamine$DB00859$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DrugDDI.d321.s1.d1$Auranofin$DB00995$Cuprimine$DB00859$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DrugDDI.d326.s0.d2$Ethoxzolamide$DB00311$Procainamide$DB01035$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DrugDDI.d326.s0.d3$Ethoxzolamide$DB00311$Quinidine$DB00908$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DrugDDI.d329.s2.d0$Dyphylline$DB00651$Probenecid$DB01032$Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
DrugDDI.d331.s2.d0$Fentanyl$DB00813$Ritonavir$DB00503$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DrugDDI.d331.s2.d1$Fentanyl$DB00813$Ketoconazole$DB01026$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DrugDDI.d331.s2.d2$Fentanyl$DB00813$Itraconazole$DB01167$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DrugDDI.d331.s2.d3$Fentanyl$DB00813$Troleandomycin$DB01361$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DrugDDI.d331.s2.d4$Fentanyl$DB00813$Clarithromycin$DB01211$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DrugDDI.d331.s2.d5$Fentanyl$DB00813$Nelfinavir$DB00220$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DrugDDI.d331.s3.d1$Diltiazem$DB00343$Fentanyl$DB00813$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DrugDDI.d331.s3.d2$Erythromycin$DB00199$Fentanyl$DB00813$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DrugDDI.d331.s5.d9$Fentanyl$DB00813$Alcohol$DB00898$Central Nervous System Depressants The concomitant use of DURAGESIC? (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DrugDDI.d332.s0.d0$Levo-Dromoran$DB00854$Alcohol$DB00898$Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DrugDDI.d332.s6.d2$Pentazocine$DB00652$Levo-Dromoran$DB00854$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DrugDDI.d332.s6.d3$Butorphanol$DB00611$Levo-Dromoran$DB00854$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DrugDDI.d332.s6.d4$Buprenorphine$DB00921$Levo-Dromoran$DB00854$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DrugDDI.d335.s0.d0$Dexbrompheniramine$DB00405$Alcohol$DB00898$Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DrugDDI.d338.s13.d1$Clomipramine$DB01242$Phenytoin$DB00252$Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
DrugDDI.d338.s13.d2$Clomipramine$DB01242$Primidone$DB00794$Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
DrugDDI.d338.s14.d0$Carbamazepine$DB00564$Lithium$DB01356$Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
DrugDDI.d338.s16.d1$Chloroquine$DB00608$Carbamazepine$DB00564$Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
DrugDDI.d338.s16.d2$Mefloquine$DB00358$Carbamazepine$DB00564$Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
DrugDDI.d34.s6.d0$Buspirone$DB00490$Warfarin$DB00682$However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
DrugDDI.d34.s8.d0$Buspirone$DB00490$Digoxin$DB00390$In vitro, buspirone may displace less firmly bound drugs like digoxin.
DrugDDI.d341.s2.d0$Probenecid$DB01032$Gemifloxacin$DB01155$Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
DrugDDI.d341.s3.d0$Factive$DB01155$Warfarin$DB00682$FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.
DrugDDI.d341.s7.d0$Magnesium$DB01378$Factive$DB01155$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DrugDDI.d341.s7.d3$Videx$DB00900$Factive$DB01155$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DrugDDI.d341.s8.d0$Sucralfate$DB00364$Factive$DB01155$Sucralfate should not be taken within 2 hours of FACTIVE.
DrugDDI.d347.s2.d0$GLUTAMINE$DB02174$Indomethacin$DB00328$Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
DrugDDI.d347.s7.d0$L-Glutamine$DB00130$Paclitaxel$DB01229$Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
DrugDDI.d35.s0.d0$Allopurinol$DB00437$Ampicillin$DB00415$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
DrugDDI.d354.s13.d0$Levothyroxine$DB00451$Ketamine$DB01221$Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
DrugDDI.d355.s0.d0$Itraconazole$DB01167$Busulfan$DB01008$Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500 ?M?min in some patients.
DrugDDI.d355.s2.d0$Phenytoin$DB00252$Busulfan$DB01008$Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
DrugDDI.d355.s3.d0$Busulfex$DB01008$Phenytoin$DB00252$Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
DrugDDI.d355.s4.d0$Busulfan$DB01008$Acetaminophen$DB00316$Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
DrugDDI.d355.s4.d1$Busulfan$DB01008$Busulfex$DB01008$Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
DrugDDI.d364.s12.d0$Ibuprofen$DB01050$Lithium$DB01356$Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
DrugDDI.d364.s15.d0$Ibuprofen$DB01050$Lithium$DB01356$Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DrugDDI.d364.s5.d0$Ibuprofen$DB01050$Methotrexate$DB00563$Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
DrugDDI.d364.s6.d0$Ibuprofen$DB01050$Methotrexate$DB00563$This may indicate that ibuprofen could enhance the toxicity of methotrexate.
DrugDDI.d364.s7.d0$Ibuprofen$DB01050$Methotrexate$DB00563$Caution should be used if ibuprofen is administered concomitantly with methotrexate.
DrugDDI.d364.s9.d0$Ibuprofen$DB01050$Furosemide$DB00695$Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
DrugDDI.d37.s4.d0$Erythromycin$DB00199$Loratadine$DB00455$Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
DrugDDI.d372.s16.d1$Quinidine$DB00908$Doxepin$DB01142$Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
DrugDDI.d372.s28.d0$Tolazamide$DB00839$Doxepin$DB01142$Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
DrugDDI.d374.s2.d0$Tranexamic Acid$DB00302$NovoSeven$DB00036$Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
DrugDDI.d374.s2.d1$Aminocaproic Acid$DB00513$NovoSeven$DB00036$Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
DrugDDI.d375.s15.d0$Tacrolimus$DB00864$Bosentan$DB00559$Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
DrugDDI.d375.s16.d0$Tacrolimus$DB00864$Bosentan$DB00559$Caution should be exercised if tacrolimus and bosentan are used together.
DrugDDI.d375.s19.d0$Bosentan$DB00559$Glyburide$DB01016$Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
DrugDDI.d375.s25.d0$Bosentan$DB00559$Simvastatin$DB00641$Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active ?-hydroxy acid metabolite, by approximately 50%.
DrugDDI.d375.s27.d1$Bosentan$DB00559$Lovastatin$DB00227$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DrugDDI.d375.s27.d2$Bosentan$DB00559$Atorvastatin$DB01076$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DrugDDI.d375.s30.d0$Bosentan$DB00559$Warfarin$DB00682$Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
DrugDDI.d377.s10.d1$Furazolidone$DB00614$Amphetamine$DB00182$MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DrugDDI.d377.s16.d0$Chlorpromazine$DB00477$Dopamine$DB00988$Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
DrugDDI.d377.s16.d1$Chlorpromazine$DB00477$Norepinephrine$DB00368$Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
DrugDDI.d377.s18.d0$Haloperidol$DB00502$Dopamine$DB00988$Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
DrugDDI.d377.s18.d1$Haloperidol$DB00502$Norepinephrine$DB00368$Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
DrugDDI.d377.s5.d1$Acetazolamide$DB00819$Amphetamine$DB00182$Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
DrugDDI.d377.s8.d0$d-amphetamine$DB01576$Desipramine$DB01151$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DrugDDI.d377.s8.d1$d-amphetamine$DB01576$Protriptyline$DB00344$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DrugDDI.d378.s13.d0$Anagrelide$DB00261$Cyclic AMP$DB02527$Anagrelide is an inhibitor of cyclic AMP PDE III.
DrugDDI.d378.s14.d1$Enoximone$DB04880$Anagrelide$DB00261$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DrugDDI.d378.s15.d0$Sucralfate$DB00364$Anagrelide$DB00261$There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
DrugDDI.d378.s8.d0$Anagrelide$DB00261$Aspirin$DB00945$Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
DrugDDI.d38.s1.d0$Aspirin$DB00945$Nicotinic Acid$DB00627$Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
DrugDDI.d382.s0.d1$Chlorotrianisene$DB00269$Aspirin$DB00945$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d10$Chlorotrianisene$DB00269$Somatropin$DB00052$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d11$Chlorotrianisene$DB00269$Tamoxifen$DB00675$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d12$Chlorotrianisene$DB00269$Warfarin$DB00682$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d3$Chlorotrianisene$DB00269$Bromocriptine$DB01200$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d4$Chlorotrianisene$DB00269$Calcium$DB01373$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d6$Chlorotrianisene$DB00269$Corticotropin$DB01285$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d7$Chlorotrianisene$DB00269$Cyclosporine$DB00091$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d8$Chlorotrianisene$DB00269$Dantrolene$DB01219$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d382.s0.d9$Chlorotrianisene$DB00269$Nicotine$DB00184$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DrugDDI.d384.s0.d0$Diflunisal$DB00861$Warfarin$DB00682$Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DrugDDI.d384.s0.d1$Diflunisal$DB00861$Acenocoumarol$DB01418$Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DrugDDI.d384.s0.d2$Diflunisal$DB00861$Phenprocoumon$DB00946$Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DrugDDI.d384.s11.d0$Diflunisal$DB00861$Acetaminophen$DB00316$Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
DrugDDI.d384.s13.d0$Diflunisal$DB00861$Acetaminophen$DB00316$Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
DrugDDI.d384.s14.d0$Diflunisal$DB00861$Acetaminophen$DB00316$Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
DrugDDI.d384.s16.d0$Diflunisal$DB00861$Methotrexate$DB00563$Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
DrugDDI.d384.s20.d0$Diflunisal$DB00861$Indomethacin$DB00328$Nonsteroidal Anti-Inflammatory Drugs The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
DrugDDI.d384.s21.d0$Indomethacin$DB00328$Diflunisal$DB00861$In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
DrugDDI.d384.s22.d0$Indomethacin$DB00328$Diflunisal$DB00861$Therefore, indomethacin and diflunisal should not be used concomitantly.
DrugDDI.d384.s25.d0$Diflunisal$DB00861$Aspirin$DB00945$Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
DrugDDI.d384.s26.d0$Diflunisal$DB00861$Sulindac$DB00605$Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
DrugDDI.d384.s27.d0$Diflunisal$DB00861$Naproxen$DB00788$Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
DrugDDI.d384.s5.d0$Diflunisal$DB00861$Hydrochlorothiazide$DB00999$Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
DrugDDI.d384.s6.d0$Diflunisal$DB00861$Hydrochlorothiazide$DB00999$Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
DrugDDI.d384.s8.d0$Diflunisal$DB00861$Furosemide$DB00695$Diflunisal decreased the hyperuricemic effect of furosemide.
DrugDDI.d385.s1.d0$Sonata$DB00962$Ethanol$DB00898$CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
DrugDDI.d385.s12.d0$Zaleplon$DB00962$Promethazine$DB01069$Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
DrugDDI.d385.s20.d0$Zaleplon$DB00962$Erythromycin$DB00199$Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
DrugDDI.d385.s22.d0$Ketoconazole$DB01026$Zaleplon$DB00962$Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
DrugDDI.d385.s29.d0$Sonata$DB00962$Cimetidine$DB00501$Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
DrugDDI.d385.s29.d1$Sonata$DB00962$Zaleplon$DB00962$Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
DrugDDI.d393.s0.d0$Acitretin$DB00459$Ethanol$DB00898$Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
DrugDDI.d393.s1.d0$Acitretin$DB00459$Glibenclamide$DB01016$Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
DrugDDI.d393.s10.d0$Acitretin$DB00459$Phenytoin$DB00252$Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
DrugDDI.d393.s12.d0$Vitamin A$DB00162$Acitretin$DB00459$Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
DrugDDI.d393.s8.d0$Methotrexate$DB00563$Etretinate$DB00926$Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
DrugDDI.d393.s9.d0$Methotrexate$DB00563$Acitretin$DB00459$Consequently, the combination of methotrexate with acitretin is also contraindicated.
DrugDDI.d397.s10.d0$Cimetidine$DB00501$Cisapride$DB00604$H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
DrugDDI.d397.s11.d0$Cimetidine$DB00501$Cisapride$DB00604$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DrugDDI.d397.s11.d1$Ranitidine$DB00863$Cisapride$DB00604$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DrugDDI.d397.s12.d0$Indinavir$DB00224$Cisapride$DB00604$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s12.d1$Ritonavir$DB00503$Cisapride$DB00604$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s2.d0$Clarithromycin$DB01211$Cisapride$DB00604$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s2.d1$Erythromycin$DB00199$Cisapride$DB00604$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s2.d2$Troleandomycin$DB01361$Cisapride$DB00604$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s3.d1$Dicyclomine$DB00804$Cisapride$DB00604$Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
DrugDDI.d397.s6.d0$Nefazodone$DB01149$Cisapride$DB00604$Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s7.d0$Fluconazole$DB00196$Cisapride$DB00604$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s7.d1$Itraconazole$DB01167$Cisapride$DB00604$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s7.d2$Ketoconazole$DB01026$Cisapride$DB00604$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DrugDDI.d397.s8.d0$Ketoconazole$DB01026$Cisapride$DB00604$Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
DrugDDI.d397.s9.d0$Cisapride$DB00604$Ketoconazole$DB01026$A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
DrugDDI.d398.s11.d0$Ketoconazole$DB01026$Aripiprazole$DB01238$When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
DrugDDI.d398.s15.d0$Aripiprazole$DB01238$Quinidine$DB00908$Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
DrugDDI.d398.s16.d0$Quinidine$DB00908$Aripiprazole$DB01238$Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
DrugDDI.d398.s19.d0$Carbamazepine$DB00564$Aripiprazole$DB01238$Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
DrugDDI.d398.s20.d0$Carbamazepine$DB00564$Aripiprazole$DB01238$When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
DrugDDI.d398.s22.d0$Carbamazepine$DB00564$Aripiprazole$DB01238$When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
DrugDDI.d398.s28.d0$Alcohol$DB00898$Abilify$DB01238$As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
DrugDDI.d398.s8.d2$Fluoxetine$DB00472$Aripiprazole$DB01238$Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
DrugDDI.d398.s9.d0$Ketoconazole$DB01026$Aripiprazole$DB01238$Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
DrugDDI.d399.s0.d3$Aspirin$DB00945$Ardeparin$DB00407$Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DrugDDI.d402.s26.d0$Crixivan$DB00224$Atazanavir$DB01072$Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
DrugDDI.d402.s35.d0$Crixivan$DB00224$Delavirdine$DB00705$Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
DrugDDI.d402.s37.d0$Indinavir$DB00224$Didanosine$DB00900$Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
DrugDDI.d402.s47.d0$Indinavir$DB00224$Nevirapine$DB00238$Indinavir concentrations may be decreased in the presence of nevirapine.
DrugDDI.d402.s52.d0$Indinavir$DB00224$Ritonavir$DB00503$Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
DrugDDI.d402.s78.d0$Crixivan$DB00224$Itraconazole$DB01167$Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
DrugDDI.d402.s84.d0$Rifabutin$DB00615$Crixivan$DB00224$Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
DrugDDI.d402.s87.d0$Sildenafil$DB00203$Indinavir$DB00224$Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
DrugDDI.d402.s90.d0$Tadalafil$DB00820$Indinavir$DB00224$Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
DrugDDI.d403.s0.d0$Lithium$DB01356$Haldol$DB00502$An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
DrugDDI.d403.s6.d0$Rifampin$DB01045$Haloperidol$DB00502$Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
DrugDDI.d405.s2.d1$Sulfinpyrazone$DB01138$Nitrofurantoin$DB00698$Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DrugDDI.d406.s3.d0$Cimetidine$DB00501$Nimodipine$DB00393$A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
DrugDDI.d406.s4.d0$Cimetidine$DB00501$Nimodipine$DB00393$This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine.
DrugDDI.d411.s2.d1$Indomethacin$DB00328$Proleukin$DB00041$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DrugDDI.d411.s2.d2$Methotrexate$DB00563$Proleukin$DB00041$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DrugDDI.d412.s0.d0$Aspirin$DB00945$Probenecid$DB01032$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DrugDDI.d412.s0.d1$Aspirin$DB00945$Sulfinpyrazone$DB01138$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DrugDDI.d412.s0.d2$Aspirin$DB00945$Phenylbutazone$DB00812$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DrugDDI.d412.s1.d0$Alcohol$DB00898$Aspirin$DB00945$Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
DrugDDI.d412.s3.d1$Phenylbutazone$DB00812$Aspirin$DB00945$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DrugDDI.d412.s3.d2$Oxyphenbutazone$DB03585$Aspirin$DB00945$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DrugDDI.d412.s3.d3$Dipyrone$DB04817$Aspirin$DB00945$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DrugDDI.d412.s6.d0$Phenobarbital$DB01174$Aspirin$DB00945$Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
DrugDDI.d412.s8.d0$Propranolol$DB00571$Aspirin$DB00945$Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
DrugDDI.d413.s2.d0$Amphotericin B$DB00681$Hydrocortisone$DB00741$In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
DrugDDI.d415.s7.d0$Glyburide$DB01016$Ciprofloxacin$DB00537$A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
DrugDDI.d417.s0.d1$Probenecid$DB01032$Penciclovir$DB00299$Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
DrugDDI.d418.s12.d1$Esomeprazole$DB00736$Ketoconazole$DB01026$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DrugDDI.d418.s12.d2$Esomeprazole$DB00736$Digoxin$DB00390$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DrugDDI.d418.s14.d0$Esomeprazole$DB00736$Clarithromycin$DB01211$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.
DrugDDI.d418.s14.d1$Esomeprazole$DB00736$Amoxicillin$DB01060$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.
DrugDDI.d418.s14.d2$Clarithromycin$DB01211$Amoxicillin$DB01060$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.
DrugDDI.d418.s15.d0$Clarithromycin$DB01211$Pimozide$DB01100$Concomitant administration of clarithromycin with pimozide is contraindicated.
DrugDDI.d418.s4.d0$Warfarin$DB00682$Esomeprazole$DB00736$Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.
DrugDDI.d418.s8.d0$Esomeprazole$DB00736$Diazepam$DB00829$Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
DrugDDI.d42.s10.d0$Ketoconazole$DB01026$Tikosyn$DB00204$Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
DrugDDI.d42.s11.d0$Trimethoprim$DB00440$Sulfamethoxazole$DB01015$Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
DrugDDI.d42.s13.d0$HCTZ$DB00999$Triamterene$DB00384$Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
DrugDDI.d42.s17.d0$HCTZ$DB00999$Triamterene$DB00384$In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and Cmax by 16%.
DrugDDI.d42.s2.d0$Cimetidine$DB00501$Tikosyn$DB00204$Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
DrugDDI.d42.s24.d1$Triamterene$DB00384$Dofetilide$DB00204$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DrugDDI.d42.s24.d2$Metformin$DB00331$Dofetilide$DB00204$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DrugDDI.d42.s24.d3$Amiloride$DB00594$Dofetilide$DB00204$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DrugDDI.d42.s27.d4$Amiodarone$DB01118$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DrugDDI.d42.s27.d5$Diltiazem$DB00343$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DrugDDI.d42.s27.d6$Norfloxacin$DB01059$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DrugDDI.d42.s27.d7$Quinine$DB00468$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DrugDDI.d42.s27.d8$Zafirlukast$DB00549$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DrugDDI.d42.s3.d0$Cimetidine$DB00501$Dofetilide$DB00204$Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
DrugDDI.d42.s30.d0$Digoxin$DB00390$Dofetilide$DB00204$In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
DrugDDI.d42.s5.d0$Tikosyn$DB00204$Cimetidine$DB00501$If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
DrugDDI.d42.s7.d0$Tikosyn$DB00204$Verapamil$DB00661$Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
DrugDDI.d42.s8.d0$Verapamil$DB00661$Dofetilide$DB00204$In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
DrugDDI.d422.s11.d0$Dexamethasone$DB01234$Aprepitant$DB00673$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
DrugDDI.d422.s13.d0$Aprepitant$DB00673$Methylprednisolone$DB00959$Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
DrugDDI.d422.s14.d0$Methylprednisolone$DB00959$Aprepitant$DB00673$The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
DrugDDI.d422.s15.d0$Aprepitant$DB00673$Warfarin$DB00682$Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
DrugDDI.d422.s18.d0$Aprepitant$DB00673$Tolbutamide$DB01124$Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
DrugDDI.d422.s22.d0$Aprepitant$DB00673$Midazolam$DB00683$Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
DrugDDI.d422.s23.d0$Midazolam$DB00683$Aprepitant$DB00673$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DrugDDI.d422.s23.d1$Alprazolam$DB00404$Aprepitant$DB00673$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DrugDDI.d422.s25.d0$Aprepitant$DB00673$Midazolam$DB00683$Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
DrugDDI.d422.s31.d1$Aprepitant$DB00673$Itraconazole$DB01167$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DrugDDI.d422.s31.d2$Aprepitant$DB00673$Troleandomycin$DB01361$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DrugDDI.d422.s31.d3$Aprepitant$DB00673$Ritonavir$DB00503$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DrugDDI.d422.s34.d1$Aprepitant$DB00673$Carbamazepine$DB00564$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DrugDDI.d422.s36.d0$Ketoconazole$DB01026$Aprepitant$DB00673$10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
DrugDDI.d422.s38.d0$Aprepitant$DB00673$Rifampin$DB01045$Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
DrugDDI.d422.s4.d0$Aprepitant$DB00673$Warfarin$DB00682$Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
DrugDDI.d422.s5.d1$Aprepitant$DB00673$Phenytoin$DB00252$Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
DrugDDI.d422.s9.d0$Aprepitant$DB00673$Dexamethasone$DB01234$Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
DrugDDI.d425.s11.d0$Grepafloxacin$DB00365$Theophylline$DB00277$Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
DrugDDI.d425.s3.d0$Caffeine$DB00201$Caffeine$DB00201$Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DrugDDI.d425.s3.d1$Caffeine$DB00201$Theobromine$DB01412$Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DrugDDI.d425.s6.d0$Theophylline$DB00277$Theophylline$DB00277$Theophylline Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
DrugDDI.d425.s7.d0$Grepafloxacin$DB00365$Theophylline$DB00277$Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
DrugDDI.d425.s8.d0$Grepafloxacin$DB00365$Theophylline$DB00277$When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
DrugDDI.d426.s1.d0$Dolasetron$DB00757$Cimetidine$DB00501$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
DrugDDI.d426.s1.d1$Dolasetron$DB00757$Rifampin$DB01045$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
DrugDDI.d428.s10.d0$Cimetidine$DB00501$Epirubicin$DB00445$Cimetidine increased the AUC of epirubicin by 50%.
DrugDDI.d428.s11.d0$Cimetidine$DB00501$Ellence$DB00445$Cimetidine treatment should be stopped during treatment with ELLENCE.
DrugDDI.d434.s1.d0$Guanfacine$DB01018$Phenobarbital$DB01174$The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
DrugDDI.d434.s5.d1$Timolol$DB00373$Guanfacine$DB01018$Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
DrugDDI.d437.s11.d1$Valproic Acid$DB00313$Mefloquine$DB00358$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DrugDDI.d437.s11.d2$Carbamazepine$DB00564$Mefloquine$DB00358$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DrugDDI.d437.s11.d3$Phenobarbital$DB01174$Mefloquine$DB00358$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DrugDDI.d437.s11.d4$Phenytoin$DB00252$Mefloquine$DB00358$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DrugDDI.d437.s4.d0$Halofantrine$DB01218$Mefloquine$DB00358$Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
DrugDDI.d437.s5.d1$Mefloquine$DB00358$Quinine$DB00468$Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DrugDDI.d437.s5.d2$Mefloquine$DB00358$Quinidine$DB00908$Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DrugDDI.d437.s5.d3$Mefloquine$DB00358$Chloroquine$DB00608$Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DrugDDI.d438.s19.d0$Carbamazepine$DB00564$Felbamate$DB00949$The carbamazepine steady-state Cmin decreased 31% to 5?1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
DrugDDI.d438.s28.d0$Felbamate$DB00949$Phenobarbital$DB01174$This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol? Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
DrugDDI.d438.s30.d0$Phenytoin$DB00252$Felbamate$DB00949$Effects of Other Antiepileptic Drugs on Felbatol? Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol? (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol? as compared to the same dose of Felbatol? given as monotherapy.
DrugDDI.d438.s33.d0$Phenobarbital$DB01174$Felbamate$DB00949$Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
DrugDDI.d438.s38.d0$Felbamate$DB00949$Gestodene$DB06730$Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
DrugDDI.d444.s0.d1$Ciprofloxacin$DB00537$Caffeine$DB00201$Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
DrugDDI.d444.s14.d0$Phenytoin$DB00252$Ciprofloxacin$DB00537$Phenytoin Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
DrugDDI.d444.s15.d0$Probenecid$DB01032$Ciprofloxacin$DB00537$Probenecid Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DrugDDI.d444.s15.d1$Probenecid$DB01032$Ciprofloxacin$DB00537$Probenecid Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DrugDDI.d444.s16.d0$Ciprofloxacin$DB00537$Theophylline$DB00277$Theophylline As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
DrugDDI.d444.s2.d1$Ciprofloxacin$DB00537$Cyclosporine$DB00091$Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
DrugDDI.d444.s5.d0$Methotrexate$DB00563$Ciprofloxacin$DB00537$Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
DrugDDI.d444.s7.d0$Methotrexate$DB00563$Ciprofloxacin$DB00537$Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
DrugDDI.d444.s8.d10$Ciprofloxacin$DB00537$Magnesium$DB01378$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DrugDDI.d444.s8.d12$Ciprofloxacin$DB00537$Sucralfate$DB00364$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DrugDDI.d444.s8.d13$Ciprofloxacin$DB00537$Videx$DB00900$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DrugDDI.d444.s8.d15$Ciprofloxacin$DB00537$Iron$DB01592$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DrugDDI.d444.s8.d16$Ciprofloxacin$DB00537$Zinc$DB01593$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DrugDDI.d452.s0.d0$Pletal$DB01166$Ketoconazole$DB01026$Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
DrugDDI.d452.s0.d1$Pletal$DB01166$Omeprazole$DB00338$Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
DrugDDI.d452.s1.d0$Omeprazole$DB00338$Erythromycin$DB00199$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DrugDDI.d452.s1.d1$Omeprazole$DB00338$Cilostazol$DB01166$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DrugDDI.d452.s1.d2$Erythromycin$DB00199$Cilostazol$DB01166$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DrugDDI.d452.s2.d0$Cilostazol$DB01166$Diltiazem$DB00343$Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
DrugDDI.d455.s18.d0$Rifampin$DB01045$Saquinavir$DB01232$Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
DrugDDI.d455.s27.d10$Cyclosporine$DB00091$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d12$Pimozide$DB01100$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d13$Carbamazepine$DB00564$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d14$Fentanyl$DB00813$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d15$Alfentanyl$DB00802$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d16$Alprazolam$DB00404$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d17$Triazolam$DB00897$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d3$Dapsone$DB00250$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d4$Disopyramide$DB00280$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d5$Quinine$DB00468$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d6$Amiodarone$DB01118$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d7$Quinidine$DB00908$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d8$Warfarin$DB00682$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s27.d9$Tacrolimus$DB00864$Saquinavir$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DrugDDI.d455.s29.d0$Invirase$DB01232$Ritonavir$DB00503$Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
DrugDDI.d455.s31.d1$Phenobarbital$DB01174$Saquinavir$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DrugDDI.d455.s31.d2$Phenytoin$DB00252$Saquinavir$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DrugDDI.d455.s31.d3$Dexamethasone$DB01234$Saquinavir$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DrugDDI.d455.s31.d4$Carbamazepine$DB00564$Saquinavir$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DrugDDI.d457.s10.d0$Almotriptan$DB00918$Ketoconazole$DB01026$Ketoconazole and Other Potent CYP3A4 Inhibitors Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
DrugDDI.d457.s2.d0$Moclobemide$DB01171$Almotriptan$DB00918$Monoamine Oxidase Inhibitors Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
DrugDDI.d457.s8.d0$Almotriptan$DB00918$Verapamil$DB00661$Verapamil Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
DrugDDI.d462.s10.d0$Itraconazole$DB01167$Cisapride$DB00604$therefore concomitant administration of Itraconazole with cisapride is contraindicated.
DrugDDI.d462.s11.d0$Itraconazole$DB01167$Midazolam$DB00683$Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DrugDDI.d462.s15.d0$Itraconazole$DB01167$Cyclosporine$DB00091$Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DrugDDI.d462.s15.d1$Itraconazole$DB01167$Digoxin$DB00390$Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DrugDDI.d462.s16.d0$Cyclosporine$DB00091$Itraconazole$DB01167$Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DrugDDI.d462.s16.d1$Digoxin$DB00390$Itraconazole$DB01167$Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DrugDDI.d462.s17.d0$Itraconazole$DB01167$Cyclosporine$DB00091$There have been rare reports of rhabdomyolysis involving renal transplant patients receiving the combination of Itraconazole, cyclosporine, and the HMG-CoA reductase inhibitors lovastatin or simvastatin.
DrugDDI.d462.s17.d1$Itraconazole$DB01167$Simvastatin$DB00641$There have been rare reports of rhabdomyolysis involving renal transplant patients receiving the combination of Itraconazole, cyclosporine, and the HMG-CoA reductase inhibitors lovastatin or simvastatin.
DrugDDI.d462.s19.d0$Itraconazole$DB01167$Phenytoin$DB00252$When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
DrugDDI.d462.s21.d0$Itraconazole$DB01167$Phenytoin$DB00252$Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
DrugDDI.d462.s22.d0$Phenytoin$DB00252$Itraconazole$DB01167$therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
DrugDDI.d462.s26.d0$Itraconazole$DB01167$Isoniazid$DB00951$Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
DrugDDI.d462.s29.d0$Itraconazole$DB01167$Quinidine$DB00908$Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
DrugDDI.d462.s3.d0$Terfenadine$DB00342$Itraconazole$DB01167$Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
DrugDDI.d462.s6.d0$Astemizole$DB00637$Itraconazole$DB01167$Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
DrugDDI.d462.s7.d0$Ketoconazole$DB01026$Cisapride$DB00604$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
DrugDDI.d462.s8.d0$Ketoconazole$DB01026$Cisapride$DB00604$Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DrugDDI.d462.s9.d0$Itraconazole$DB01167$Cisapride$DB00604$In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
DrugDDI.d463.s0.d4$Alprazolam$DB00404$Ethanol$DB00898$The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DrugDDI.d463.s1.d0$Imipramine$DB00458$Alprazolam$DB00404$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
DrugDDI.d463.s5.d0$Fluoxetine$DB00472$Alprazolam$DB00404$Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Fluoxetine: Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
DrugDDI.d465.s0.d0$Cytosine arabinoside$DB00987$Flucytosine$DB01099$Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
DrugDDI.d469.s0.d0$Heparin$DB01109$Argatroban$DB00278$Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
DrugDDI.d469.s1.d0$Argatroban$DB00278$Heparin$DB01109$However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.
DrugDDI.d469.s2.d0$Argatroban$DB00278$Aspirin$DB00945$Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1 ?g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5 ?g/kg/min. over 18 hours).
DrugDDI.d469.s4.d0$Argatroban$DB00278$Warfarin$DB00682$However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
DrugDDI.d47.s1.d1$Reserpine$DB00206$Zebeta$DB00612$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
DrugDDI.d47.s1.d2$Guanethidine$DB01170$Zebeta$DB00612$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
DrugDDI.d47.s2.d0$Zebeta$DB00612$Clonidine$DB00575$In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
DrugDDI.d47.s3.d1$Zebeta$DB00612$Verapamil$DB00661$ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DrugDDI.d47.s4.d0$Rifampin$DB01045$Zebeta$DB00612$Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
DrugDDI.d472.s0.d0$Warfarin$DB00682$Flutamide$DB00499$Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
DrugDDI.d474.s2.d1$Nitroglycerin$DB00727$INOmax$DB00435$Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
DrugDDI.d476.s13.d0$Phenytoin$DB00252$Flecainide$DB01195$Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DrugDDI.d476.s13.d1$Phenobarbital$DB01174$Flecainide$DB01195$Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DrugDDI.d476.s13.d2$Carbamazepine$DB00564$Flecainide$DB01195$Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DrugDDI.d476.s14.d0$Cimetidine$DB00501$Flecainide$DB01195$In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
DrugDDI.d476.s15.d0$Amiodarone$DB01118$Flecainide$DB01195$When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
DrugDDI.d476.s16.d1$Quinidine$DB00908$Flecainide$DB01195$Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
DrugDDI.d476.s19.d0$Tambocor$DB01195$Disopyramide$DB00280$Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
DrugDDI.d476.s19.d1$Disopyramide$DB00280$Verapamil$DB00661$Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
DrugDDI.d476.s2.d0$Tambocor$DB01195$Digoxin$DB00390$During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
DrugDDI.d476.s3.d0$Tambocor$DB01195$Propranolol$DB00571$In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
DrugDDI.d476.s4.d0$Tambocor$DB01195$Propranolol$DB00571$In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;
DrugDDI.d476.s6.d0$Tambocor$DB01195$Propranolol$DB00571$The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
DrugDDI.d478.s2.d0$Lincomycin$DB01627$Erythromycin$DB00199$Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
DrugDDI.d487.s0.d1$Butorphanol$DB00611$Alcohol$DB00898$Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DrugDDI.d489.s0.d0$Cyclophosphamide$DB00531$Phenobarbital$DB01174$The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
DrugDDI.d491.s1.d0$Nabumetone$DB00461$Warfarin$DB00682$Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
DrugDDI.d492.s11.d0$Warfarin$DB00682$Nevirapine$DB00238$When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
DrugDDI.d492.s18.d0$Clarithromycin$DB01211$Nevirapine$DB00238$Clarithromycin exposure was significantly decreased by nevirapine;
DrugDDI.d492.s36.d0$Nevirapine$DB00238$Ketoconazole$DB01026$Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
DrugDDI.d492.s53.d0$Nevirapine$DB00238$Rifampin$DB01045$Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
DrugDDI.d492.s58.d1$Nevirapine$DB00238$Methadone$DB00333$aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
DrugDDI.d494.s0.d0$Ethopropazine$DB00392$Alcohol$DB00898$Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
DrugDDI.d494.s2.d0$Ethopropazine$DB00392$Chlorpromazine$DB00477$Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
DrugDDI.d496.s10.d0$Ciprofloxacin$DB00537$Didanosine$DB00900$The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
DrugDDI.d496.s11.d0$Ciprofloxacin$DB00537$Didanosine$DB00900$In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
DrugDDI.d496.s14.d0$Delavirdine$DB00705$Videx$DB00900$Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
DrugDDI.d496.s14.d1$Indinavir$DB00224$Videx$DB00900$Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
DrugDDI.d496.s15.d0$Delavirdine$DB00705$Videx$DB00900$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
DrugDDI.d496.s15.d1$Indinavir$DB00224$Videx$DB00900$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
DrugDDI.d496.s2.d0$Allopurinol$DB00437$Videx$DB00900$Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
DrugDDI.d496.s6.d0$Videx$DB00900$Ganciclovir$DB01004$Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
DrugDDI.d496.s7.d0$Videx$DB00900$Ganciclovir$DB01004$A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
DrugDDI.d496.s8.d0$Videx$DB00900$Ciprofloxacin$DB00537$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DrugDDI.d498.s6.d0$Lamivudine$DB00709$Zalcitabine$DB00943$Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
DrugDDI.d498.s7.d0$Lamivudine$DB00709$Zalcitabine$DB00943$Therefore, use of lamivudine in combination with zalcitabine is not recommended
DrugDDI.d501.s0.d0$Apomorphine$DB00714$Ondansetron$DB00904$5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DrugDDI.d501.s0.d1$Apomorphine$DB00714$Ondansetron$DB00904$5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DrugDDI.d501.s0.d2$Apomorphine$DB00714$Dolasetron$DB00757$5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DrugDDI.d501.s0.d3$Apomorphine$DB00714$Alosetron$DB00969$5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DrugDDI.d501.s3.d2$Metoclopramide$DB01233$Apokyn$DB00714$Dopamine Antagonists Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenoth-iazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DrugDDI.d504.s12.d1$Lansoprazole$DB00448$Ampicillin$DB00415$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DrugDDI.d504.s3.d0$Lansoprazole$DB00448$Theophylline$DB00277$When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
DrugDDI.d504.s5.d0$Theophylline$DB00277$Lansoprazole$DB00448$Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
DrugDDI.d506.s0.d0$Eszopiclone$DB00402$Ethanol$DB00898$CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
DrugDDI.d506.s10.d0$Rifampicin$DB01045$Zopiclone$DB01198$Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
DrugDDI.d506.s7.d0$Eszopiclone$DB00402$Ketoconazole$DB01026$The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
DrugDDI.d507.s1.d0$Colchicine$DB01394$Vitamin B12$DB00115$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
DrugDDI.d508.s1.d0$Angiomax$DB00006$Heparin$DB01109$In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
DrugDDI.d508.s1.d1$Angiomax$DB00006$Warfarin$DB00682$In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
DrugDDI.d509.s7.d0$Ranitidine$DB00863$Ceftibuten$DB01415$however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
DrugDDI.d513.s3.d1$Levobupivacaine$DB01002$Phenobarbital$DB01174$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DrugDDI.d516.s0.d0$Dexamethasone$DB01234$Albendazole$DB00518$Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
DrugDDI.d517.s1.d0$Robinul$DB00986$Potassium Chloride$DB00761$Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
DrugDDI.d521.s1.d0$Lorazepam$DB00186$Ethyl Alcohol$DB00898$Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DrugDDI.d521.s1.d5$Scopolamine$DB00747$Lorazepam$DB00186$Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DrugDDI.d523.s14.d0$Aspirin$DB00945$Celebrex$DB00482$However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
DrugDDI.d523.s16.d0$Fluconazole$DB00196$Celecoxib$DB00482$Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
DrugDDI.d523.s17.d0$Celecoxib$DB00482$Fluconazole$DB00196$This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
DrugDDI.d523.s18.d0$Celebrex$DB00482$Fluconazole$DB00196$CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
DrugDDI.d523.s19.d0$Lithium$DB01356$Celebrex$DB00482$Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
DrugDDI.d523.s20.d0$Lithium$DB01356$Celebrex$DB00482$Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
DrugDDI.d523.s24.d0$Celebrex$DB00482$Warfarin$DB00682$However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
DrugDDI.d523.s6.d0$Celecoxib$DB00482$Fluconazole$DB00196$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DrugDDI.d523.s6.d1$Celecoxib$DB00482$Lithium$DB01356$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DrugDDI.d525.s38.d0$Methotrexate$DB00563$Sulfapyridine$DB00891$- Methotrexate (e.g., Mexate)?Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
DrugDDI.d525.s39.d0$Methyldopa$DB00968$Sulfapyridine$DB00891$- Methyldopa (e.g., Aldomet)?Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
DrugDDI.d525.s40.d0$Phenytoin$DB00252$Sulfapyridine$DB00891$- Phenytoin (e.g., Dilantin)?Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
DrugDDI.d527.s0.d0$Pegasys$DB00008$Theophylline$DB00277$Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
DrugDDI.d527.s1.d0$Theophylline$DB00277$Pegasys$DB00008$Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
DrugDDI.d527.s4.d0$Copegus$DB00811$Didanosine$DB00900$Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
DrugDDI.d527.s6.d0$Zidovudine$DB00495$Stavudine$DB00649$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DrugDDI.d527.s6.d1$Zidovudine$DB00495$Zidovudine$DB00495$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DrugDDI.d529.s4.d0$Anakinra$DB00026$Humira$DB00051$Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
DrugDDI.d531.s1.d0$Vioxx$DB00533$Benazepril$DB00542$In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
DrugDDI.d531.s16.d0$Lithium$DB01356$Lithium$DB01356$Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DrugDDI.d531.s18.d0$Vioxx$DB00533$Lithium$DB01356$Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DrugDDI.d531.s20.d0$Vioxx$DB00533$Methotrexate$DB00563$At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
DrugDDI.d531.s21.d0$Methotrexate$DB00563$Rofecoxib$DB00533$At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
DrugDDI.d531.s22.d0$Vioxx$DB00533$Methotrexate$DB00563$Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
DrugDDI.d531.s28.d0$Vioxx$DB00533$Theophylline$DB00277$Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
DrugDDI.d531.s3.d0$Aspirin$DB00945$Vioxx$DB00533$Aspirin Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
DrugDDI.d531.s31.d0$Vioxx$DB00533$Warfarin$DB00682$Warfarin Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
DrugDDI.d531.s32.d0$Warfarin$DB00682$Rofecoxib$DB00533$In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
DrugDDI.d531.s33.d0$Vioxx$DB00533$Warfarin$DB00682$In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
DrugDDI.d533.s11.d0$Lodine$DB00749$Furosemide$DB00695$Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
DrugDDI.d533.s15.d0$Lithium$DB01356$Lithium$DB01356$Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DrugDDI.d533.s19.d0$Phenylbutazone$DB00812$Etodolac$DB00749$Phenylbutazone Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
DrugDDI.d533.s20.d0$Etodolac$DB00749$Phenylbutazone$DB00812$Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
DrugDDI.d533.s23.d0$Warfarin$DB00682$Etodolac$DB00749$Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine? (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
DrugDDI.d533.s26.d0$Etodolac$DB00749$Warfarin$DB00682$However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
DrugDDI.d533.s4.d0$Lodine$DB00749$Aspirin$DB00945$Aspirin When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
DrugDDI.d533.s6.d0$Lodine$DB00749$Aspirin$DB00945$however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
DrugDDI.d535.s0.d0$Bismuth Subsalicylate$DB01294$Enoxacin$DB00467$Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
DrugDDI.d535.s1.d0$Enoxacin$DB00467$Bismuth Subsalicylate$DB01294$Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
DrugDDI.d535.s17.d1$Aluminum hydroxide$DB06723$Enoxacin$DB00467$Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
DrugDDI.d535.s18.d0$Enoxacin$DB00467$Ranitidine$DB00863$The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
DrugDDI.d535.s21.d0$Enoxacin$DB00467$Theophylline$DB00277$Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
DrugDDI.d535.s22.d0$Theophylline$DB00277$Enoxacin$DB00467$Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
DrugDDI.d535.s25.d0$Warfarin$DB00682$Enoxacin$DB00467$Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
DrugDDI.d535.s3.d0$Enoxacin$DB00467$Caffeine$DB00201$In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
DrugDDI.d535.s4.d0$Caffeine$DB00201$Enoxacin$DB00467$Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
DrugDDI.d535.s5.d0$Caffeine$DB00201$Enoxacin$DB00467$Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
DrugDDI.d535.s8.d0$Enoxacin$DB00467$Digoxin$DB00390$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
DrugDDI.d536.s24.d0$Hydrocodone$DB00956$Gabapentin$DB00996$Hydrocodone increases gabapentin AUC values by 14%.
DrugDDI.d536.s29.d0$Cimetidine$DB00501$Gabapentin$DB00996$Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
DrugDDI.d536.s30.d0$Cimetidine$DB00501$Gabapentin$DB00996$Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
DrugDDI.d536.s31.d0$Gabapentin$DB00996$Cimetidine$DB00501$This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
DrugDDI.d536.s35.d0$Norethindrone$DB00717$Gabapentin$DB00996$The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
DrugDDI.d537.s1.d0$Phenytoin$DB00252$Fluorouracil$DB00544$Concomitant administration of phenytoin and ERGAMISOL? plus fluorouracil has lead to increased plasma levels of phenytoin.
DrugDDI.d538.s3.d0$Aspirin$DB00945$Nizatidine$DB00585$In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
DrugDDI.d54.s12.d0$Valdecoxib$DB00580$Phenytoin$DB00252$Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
DrugDDI.d54.s13.d0$Valdecoxib$DB00580$Phenytoin$DB00252$Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
DrugDDI.d54.s18.d0$Valdecoxib$DB00580$Dextromethorphan$DB00514$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
DrugDDI.d54.s21.d0$Bextra$DB00580$Lithium$DB01356$Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
DrugDDI.d54.s24.d0$Valdecoxib$DB00580$Warfarin$DB00682$Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DrugDDI.d54.s24.d1$Valdecoxib$DB00580$Warfarin$DB00682$Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DrugDDI.d54.s26.d0$Bextra$DB00580$Warfarin$DB00682$Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
DrugDDI.d54.s29.d0$Valdecoxib$DB00580$Fluconazole$DB00196$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DrugDDI.d54.s29.d1$Valdecoxib$DB00580$Ketoconazole$DB01026$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DrugDDI.d54.s29.d2$Fluconazole$DB00196$Ketoconazole$DB01026$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DrugDDI.d54.s33.d0$Valdecoxib$DB00580$Glyburide$DB01016$Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
DrugDDI.d54.s39.d0$Valdecoxib$DB00580$Omeprazole$DB00338$Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
DrugDDI.d54.s4.d0$Aspirin$DB00945$Valdecoxib$DB00580$Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
DrugDDI.d54.s40.d0$Omeprazole$DB00338$Valdecoxib$DB00580$Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.
DrugDDI.d54.s48.d0$Diazepam$DB00829$Valdecoxib$DB00580$Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
DrugDDI.d540.s0.d1$Netilmicin$DB00955$Ethacrynic acid$DB00903$Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DrugDDI.d542.s2.d0$Pyridoxine$DB00165$Hexalen$DB00488$however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
DrugDDI.d551.s0.d0$Phenytoin$DB00252$Norpace$DB00280$If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
DrugDDI.d551.s5.d0$Norpace$DB00280$Quinidine$DB00908$Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
DrugDDI.d551.s9.d0$Disopyramide$DB00280$Verapamil$DB00661$Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
DrugDDI.d553.s1.d0$Nimbex$DB00565$Succinylcholine$DB00202$Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced ?95% neuromuscular block.
DrugDDI.d553.s10.d0$Enflurane$DB00228$Nimbex$DB00565$In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
DrugDDI.d553.s10.d1$Isoflurane$DB00753$Nimbex$DB00565$In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
DrugDDI.d556.s0.d0$Cytadren$DB00357$Dexamethasone$DB01234$Cytadren accelerates the metabolism of dexamethasone;
DrugDDI.d559.s10.d0$Fluvoxamine$DB00176$Alprazolam$DB00404$Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
DrugDDI.d559.s11.d0$Fluvoxamine$DB00176$Terbinafine$DB00857$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DrugDDI.d559.s11.d1$Fluvoxamine$DB00176$Astemizole$DB00637$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DrugDDI.d559.s11.d2$Fluvoxamine$DB00176$Cisapride$DB00604$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DrugDDI.d559.s12.d1$Alprazolam$DB00404$Fluvoxamine$DB00176$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DrugDDI.d559.s12.d2$Midazolam$DB00683$Fluvoxamine$DB00176$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DrugDDI.d559.s12.d3$Triazolam$DB00897$Fluvoxamine$DB00176$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DrugDDI.d559.s14.d0$Fluvoxamine$DB00176$Alprazolam$DB00404$Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
DrugDDI.d559.s19.d0$Fluvoxamine$DB00176$Diazepam$DB00829$Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
DrugDDI.d559.s20.d0$Fluvoxamine$DB00176$Diazepam$DB00829$Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
DrugDDI.d559.s21.d0$Fluvoxamine$DB00176$Diazepam$DB00829$Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
DrugDDI.d559.s24.d0$Alprazolam$DB00404$Fluvoxamine$DB00176$Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
DrugDDI.d559.s25.d0$Diazepam$DB00829$Fluvoxamine$DB00176$Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
DrugDDI.d559.s28.d0$Theophylline$DB00277$Fluvoxamine$DB00176$Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
DrugDDI.d559.s30.d0$Fluvoxamine$DB00176$Warfarin$DB00682$Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
DrugDDI.d559.s7.d0$Terfenadine$DB00342$Ketoconazole$DB01026$Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DrugDDI.d559.s7.d1$Astemizole$DB00637$Ketoconazole$DB01026$Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DrugDDI.d559.s7.d2$Cisapride$DB00604$Ketoconazole$DB01026$Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DrugDDI.d561.s0.d0$Gleevec$DB00619$Ketoconazole$DB01026$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DrugDDI.d561.s0.d1$Gleevec$DB00619$Erythromycin$DB00199$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DrugDDI.d561.s15.d0$Gleevec$DB00619$Acetaminophen$DB00316$in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5 ?M) at therapeutic levels.
DrugDDI.d561.s16.d0$Acetaminophen$DB00316$Gleevec$DB00619$Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
DrugDDI.d561.s2.d0$Gleevec$DB00619$Ketoconazole$DB01026$There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
DrugDDI.d561.s6.d0$Rifampin$DB01045$Gleevec$DB00619$Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
DrugDDI.d561.s8.d0$Gleevec$DB00619$Simvastatin$DB00641$Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
DrugDDI.d561.s9.d0$Gleevec$DB00619$Cyclosporine$DB00091$Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
DrugDDI.d564.s12.d1$Alcohol$DB00898$Romazicon$DB01205$Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
DrugDDI.d566.s3.d1$Lithium$DB01356$Bumetanide$DB00887$- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
DrugDDI.d566.s4.d0$Probenecid$DB01032$Bumetanide$DB00887$- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
DrugDDI.d566.s5.d0$Probenecid$DB01032$Bumetanide$DB00887$This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
DrugDDI.d566.s6.d0$Probenecid$DB01032$Bumetanide$DB00887$Thus, probenecid should not be administered concurrently with bumetanide.
DrugDDI.d566.s7.d0$Indomethacin$DB00328$Bumetanide$DB00887$- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
DrugDDI.d568.s0.d0$Albuterol$DB01001$Albuterol$DB01001$Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
DrugDDI.d568.s3.d1$Strattera$DB00289$Fluoxetine$DB00472$Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
DrugDDI.d568.s4.d0$Paroxetine$DB00715$Atomoxetine$DB00289$In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
DrugDDI.d576.s1.d0$Cyclosporin A$DB00091$Etoposide$DB00773$High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
DrugDDI.d579.s10.d0$Tiagabine$DB00906$Carbamazepine$DB00564$Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
DrugDDI.d579.s11.d0$Tiagabine$DB00906$Phenytoin$DB00252$Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
DrugDDI.d579.s12.d0$Tiagabine$DB00906$Phenobarbital$DB01174$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DrugDDI.d579.s12.d1$Tiagabine$DB00906$Primidone$DB00794$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DrugDDI.d579.s23.d1$Ethanol$DB00898$Triazolam$DB00897$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
DrugDDI.d579.s7.d0$Tiagabine$DB00906$Valproate$DB00313$Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
DrugDDI.d58.s17.d0$Cimetidine$DB00501$Clozapine$DB00363$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DrugDDI.d58.s17.d1$Caffeine$DB00201$Clozapine$DB00363$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DrugDDI.d58.s17.d2$Erythromycin$DB00199$Clozapine$DB00363$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DrugDDI.d58.s18.d0$Clozapine$DB00363$Carbamazepine$DB00564$Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
DrugDDI.d58.s21.d0$Paroxetine$DB00715$Clozapine$DB00363$Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
DrugDDI.d58.s22.d0$Clozapine$DB00363$Paroxetine$DB00715$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DrugDDI.d58.s22.d1$Clozapine$DB00363$Fluoxetine$DB00472$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DrugDDI.d58.s22.d2$Clozapine$DB00363$Sertraline$DB01104$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DrugDDI.d58.s30.d2$Clozapine$DB00363$Carbamazepine$DB00564$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DrugDDI.d58.s30.d3$Clozapine$DB00363$Propafenone$DB01182$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DrugDDI.d58.s30.d4$Clozapine$DB00363$Flecainide$DB01195$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DrugDDI.d58.s30.d5$Clozapine$DB00363$Encainide$DB01228$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DrugDDI.d58.s30.d6$Clozapine$DB00363$Quinidine$DB00908$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DrugDDI.d58.s9.d1$Clozapine$DB00363$Atropine$DB00572$Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
DrugDDI.d581.s0.d0$Foscavir$DB00529$Pentamidin$DB00738$A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
DrugDDI.d581.s1.d0$Foscavir$DB00529$Pentamidin$DB00738$Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
DrugDDI.d581.s4.d1$Foscavir$DB00529$Amphotericin B$DB00681$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
DrugDDI.d581.s5.d0$Ritonavir$DB00503$Foscavir$DB00529$Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir.
DrugDDI.d63.s0.d0$Etidronate$DB01077$Warfarin$DB00682$There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
DrugDDI.d64.s1.d0$Duloxetine$DB00476$Fluvoxamine$DB00176$Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
DrugDDI.d64.s11.d0$Duloxetine$DB00476$Thioridazine$DB00679$Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
DrugDDI.d64.s4.d0$Paroxetine$DB00715$Duloxetine$DB00476$Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
DrugDDI.d64.s8.d0$Duloxetine$DB00476$Desipramine$DB01151$When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
DrugDDI.d64.s9.d3$Duloxetine$DB00476$Nortriptyline$DB00540$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DrugDDI.d64.s9.d4$Duloxetine$DB00476$Amitriptyline$DB00321$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DrugDDI.d64.s9.d5$Duloxetine$DB00476$Imipramine$DB00458$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DrugDDI.d64.s9.d8$Duloxetine$DB00476$Propafenone$DB01182$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DrugDDI.d64.s9.d9$Duloxetine$DB00476$Flecainide$DB01195$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DrugDDI.d65.s0.d0$Digoxin$DB00390$Conivaptan$DB00872$Digoxin Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
DrugDDI.d66.s16.d0$Ampicillin$DB00415$Allopurinol$DB00437$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
DrugDDI.d66.s18.d0$Cyclophosphamide$DB00531$Allopurinol$DB00437$Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
DrugDDI.d66.s2.d0$Allopurinol$DB00437$Mercaptopurine$DB01033$Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DrugDDI.d66.s2.d1$Allopurinol$DB00437$Azathioprine$DB00993$Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DrugDDI.d66.s20.d0$Chlorpropamide$DB00672$Allopurinol$DB00437$Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
DrugDDI.d66.s21.d0$Allopurinol$DB00437$Chlorpropamide$DB00672$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
DrugDDI.d66.s4.d0$Allopurinol$DB00437$Mercaptopurine$DB01033$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
DrugDDI.d66.s7.d0$Allopurinol$DB00437$Dicumarol$DB00266$The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
DrugDDI.d68.s4.d1$Carbamazepine$DB00564$Estazolam$DB01215$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DrugDDI.d68.s4.d2$Phenytoin$DB00252$Estazolam$DB01215$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DrugDDI.d68.s4.d3$Rifampin$DB01045$Estazolam$DB01215$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DrugDDI.d68.s6.d0$Estazolam$DB01215$Ketoconazole$DB01026$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DrugDDI.d68.s6.d1$Estazolam$DB01215$Itraconazole$DB01167$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DrugDDI.d69.s2.d0$Heroin$DB01452$Alcohol$DB00898$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DrugDDI.d69.s2.d1$Heroin$DB01452$Diazepam$DB00829$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DrugDDI.d69.s2.d2$Heroin$DB01452$Methadone$DB00333$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DrugDDI.d69.s4.d0$Cocaine$DB00907$Heroin$DB01452$Cocaine sometimes proves to be fatal when used in combination with heroin.
DrugDDI.d7.s2.d1$Rifampicin$DB01045$Exemestane$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.
DrugDDI.d7.s2.d2$Phenytoin$DB00252$Exemestane$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.
DrugDDI.d7.s2.d3$Carbamazepine$DB00564$Exemestane$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.
DrugDDI.d7.s2.d4$Phenobarbital$DB01174$Exemestane$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.
DrugDDI.d71.s7.d0$Chlorthalidone$DB00310$Tubocurarine$DB01199$Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
DrugDDI.d71.s8.d0$Chlorthalidone$DB00310$Norepinephrine$DB00368$Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
DrugDDI.d76.s5.d0$Probenecid$DB01032$Ampicillin$DB00415$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
DrugDDI.d80.s3.d0$Cinacalcet$DB01012$Amitriptyline$DB00321$Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
DrugDDI.d80.s6.d0$Ketoconazole$DB01026$Sensipar$DB01012$Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
DrugDDI.d82.s12.d0$Cimetidine$DB00501$Diltiazem$DB00343$A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
DrugDDI.d82.s15.d0$Diltiazem$DB00343$Cimetidine$DB00501$Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
DrugDDI.d82.s25.d0$Diltiazem$DB00343$Cyclosporine$DB00091$A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
DrugDDI.d82.s27.d0$Cyclosporine$DB00091$Diltiazem$DB00343$If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
DrugDDI.d82.s30.d0$Diltiazem$DB00343$Carbamazepine$DB00564$Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
DrugDDI.d82.s33.d0$Diltiazem$DB00343$Midazolam$DB00683$Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
DrugDDI.d82.s33.d1$Diltiazem$DB00343$Triazolam$DB00897$Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
DrugDDI.d82.s34.d0$Midazolam$DB00683$Diltiazem$DB00343$The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
DrugDDI.d82.s34.d1$Triazolam$DB00897$Diltiazem$DB00343$The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
DrugDDI.d82.s35.d0$Diltiazem$DB00343$Midazolam$DB00683$These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
DrugDDI.d82.s35.d1$Diltiazem$DB00343$Triazolam$DB00897$These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
DrugDDI.d82.s37.d0$Diltiazem$DB00343$Lovastatin$DB00227$In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
DrugDDI.d82.s41.d0$Rifampin$DB01045$Diltiazem$DB00343$Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
DrugDDI.d82.s42.d0$Diltiazem$DB00343$Rifampin$DB01045$Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
DrugDDI.d82.s9.d0$Propranolol$DB00571$Diltiazem$DB00343$In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
DrugDDI.d86.s10.d0$Amprenavir$DB00701$Methadone$DB00333$Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
DrugDDI.d86.s13.d0$Amprenavir$DB00701$Ritonavir$DB00503$Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
DrugDDI.d86.s14.d0$Amprenavir$DB00701$Ritonavir$DB00503$Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
DrugDDI.d86.s5.d0$Indinavir$DB00224$Amprenavir$DB00701$Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
DrugDDI.d86.s7.d0$Saquinavir$DB01232$Amprenavir$DB00701$Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
DrugDDI.d86.s8.d0$Nelfinavir$DB00220$Amprenavir$DB00701$Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
DrugDDI.d86.s9.d0$Amprenavir$DB00701$Methadone$DB00333$Methadone: Coadministration of amprenavir and methadone can decrease plasma levels ofmethadone.
DrugDDI.d87.s3.d0$Clonazepam$DB01068$Propantheline$DB00782$In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
DrugDDI.d87.s5.d1$Phenytoin$DB00252$Clonazepam$DB01068$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DrugDDI.d87.s5.d2$Carbamazepine$DB00564$Clonazepam$DB01068$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DrugDDI.d87.s5.d3$Phenobarbital$DB01174$Clonazepam$DB01068$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DrugDDI.d89.s2.d0$Theophylline$DB00277$Cetirizine$DB00341$In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
DrugDDI.d89.s5.d0$Cetirizine$DB00341$Theophylline$DB00277$There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
DrugDDI.d91.s24.d1$Anafranil$DB01242$Warfarin$DB00682$Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
DrugDDI.d91.s24.d2$Anafranil$DB01242$Digoxin$DB00390$Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
DrugDDI.d91.s6.d4$Methylphenidate$DB00422$Cimetidine$DB00501$plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DrugDDI.d91.s6.d5$Methylphenidate$DB00422$Fluoxetine$DB00472$plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DrugDDI.d92.s0.d0$Azathioprine$DB00993$Allopurinol$DB00437$Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
DrugDDI.d92.s1.d0$Azathioprine$DB00993$Allopurinol$DB00437$Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
DrugDDI.d93.s2.d0$Phenytoin$DB00252$Calcitriol$DB00136$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DrugDDI.d93.s2.d1$Phenobarbital$DB01174$Calcitriol$DB00136$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DrugDDI.d93.s3.d0$Calcitriol$DB00136$Rocaltrol$DB00136$Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
DrugDDI.d99.s0.d0$Lofexidine$DB04948$Alcohol$DB00898$- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
